Category Archives: Transhuman News

In Silicon Valley, Moore's law seems to stand on equal footing with the natural laws codified by Isaac Newton. Intel co-founder Gordon Moore's iconic observation that computing power tends to double and that its price therefore halves every 2 years has held true for nearly 50 years with only minor revision. But as an exemplar of rapid change, it is the target of playful abuse from genome researchers.

In dozens of presentations over the past few years, scientists have compared the slope of Moore's law with the swiftly dropping costs of DNA sequencing. For a while they kept pace, but since about 2007, it has not even been close. The price of sequencing an average human genome has plummeted from about US$10 million to a few thousand dollars in just six years (see Falling fast). That does not just outpace Moore's law it makes the once-powerful predictor of unbridled progress look downright sedate. And just as the easy availability of personal computers changed the world, the breakneck pace of genome-technology development has revolutionized bioscience research. It is also set to cause seismic shifts in medicine.

In the eyes of many, a fair share of the credit for this success goes to a grant scheme run by the US National Human Genome Research Institute (NHGRI). Officially called the Advanced Sequencing Technology awards, it is known more widely as the $1,000 and $100,000 genome programmes. Started in 2004, the scheme has awarded grants to 97 groups of academic and industrial scientists, including some at every major sequencing company.

It has encouraged mobility and cooperation among technologists, and helped to launch dozens of competing companies, staving off the stagnation that many feared would take hold after the Human Genome Project wrapped up in 2003. The major companies in the space have really changed the way people do sequencing, and it all started with the NHGRI funding, says Gina Costa, who has worked for five influential companies and is now a vice-president at Cypher Genomics, a genome-interpretation firm in San Diego, California.

The $1,000 genome programme, now close to achieving its goal, will award its final grants this year. As technology enthusiasts look to future challenges, the coming milestone raises questions about how the roughly $230-million government programme managed to achieve such success, and whether its winning formula can be applied elsewhere. It benefited from fortuitous timing and the lack of an entrenched industry. But Jeffery Schloss, director of the division of genome sciences at the NHGRI in Bethesda, Maryland, who has run the programme from its inception, says that its achievements also suggest that there are ways to navigate publicprivate partnerships successfully. One of our challenges is to figure out what is the right role for the government; to not get in the way, but feed the pipeline of private-sector technology development, he says.

The quest to sequence the first human genome was a massive undertaking. Between 1990 and the publication of a working draft in 2001, more than 200 scientists joined forces in a $3-billion effort to read the roughly 3 billion bases of DNA that comprise our genetic material (International Human Genome Sequencing Consortium Nature 409, 860921; 2001). It was a grand but sobering success. The project's advocates had said that it would reveal 'life's instruction book', but in fact it did not make it possible to interpret how the instructions encoded in DNA were transformed into biology. Understanding how DNA actually influences health and disease would require studying examples of the links between genes and biology in thousands, perhaps millions, more people.

The dominant technology at the time was Sanger sequencing, an inherently slow, labour-intensive process that works by making copies of the DNA to be sequenced that include chemically modified and fluorescently tagged versions of the molecule's building blocks. One company, Applied Biosystems in Foster City, California, provided the vast majority of the sequencers to a limited number of customers generally, large government-funded laboratories and there was little incentive for it to reinvent its core technology.

Still, researchers had seen some advances, including robots that replaced some human work and improvements in devices capable of handling small amounts of liquid. At a 2002 meeting convened by the NHGRI, scientists predicted that such developments would drive costs down at least 100-fold over the next five years. But that was not enough.

They debated what price target would make human genome sequencing routine, the kind of thing a physician might order to help diagnose a patient on a par with a magnetic resonance imaging scan. Somebody threw out, to great rolling of eyes, 'a thousand dollars', recalls Schloss.

That seemed too ambitious, given the state of the technology. The risk associated with that is not one that your normal investor is willing to spend any money on, says Eric Eisenstadt, a retired official from the US government's Defense Advanced Research Project Agency who is now a consultant in Reston, Virginia.

See more here:
Technology: The $1,000 genome

PUBLIC RELEASE DATE:

20-Mar-2014

Contact: C. Dana Nelson dananelson@fs.fed.us 228-832-2747 x202 USDA Forest Service Southern Research Station

U.S. Forest Service Southern Research Station (SRS) scientists co-authored the article published today in the journal Genome Biology that reports the sequencing, assembly, and annotation of the loblolly pine (Pinus taeda) genome. As the primary source of pulpwood and saw timber for the U.S. forest industry, loblolly pine is of great economic importance to the South and the nation. David Neale, professor of plant sciences at the University of California, Davis, led the loblolly pine genome project.

"The project was a huge undertaking because at 22 gigabases, the loblolly pine genome is about eight times larger than the human genome," said C. Dana Nelson, SRS Southern Institute for Forest Genetics (SIFG) project leader and research geneticist. "The group chose loblolly pine both because of its economic importance, and the knowledge gained from 60 years of breeding the species and managing millions of trees in genetic trials."

As part of the project, researchers identified a candidate for a gene involved in resistance to fusiform rust, a disease that infects southern pines. SIFG biological science technician Katherine Smith worked with John M. Davis, professor and associate director of the School of Forest Resources and Conservation at the University of Florida (UF), to compare mapped sections of the genome with sections found in loblolly specimens previously inoculated with the pathogen that causes fusiform rust.

"Fusiform rust is the most damaging disease of southern pinesand one of the most complex due to genetic interactions between the pathogen and its host," said Davis, who also serves as faculty and Executive Committee member at the UF Genetics Institute. "Genetic resistance is the only realistic way to manage the disease, which infects young trees within their first five years of growth and weakens or girdles the stem. Chemical control is expensive, impractical, and not very good for the environment."

Researchers and breeders can use the resistance genes as markers to track resistance in pine breeding populations and to guide tree planting at the stand level. "The fusiform rust pathogen has evolved to defeat some rust resistance genes in loblolly," said Nelson. "The increased molecular understanding from the loblolly genome sequencing effort provides managers with a new effective tool to determine how well seedlings will grow on a particular site."

SIFG involvement in sequencing the loblolly genome actually goes back at least two decades, when SIFG helped develop an array of resources to help speed up mapping and sequencing the loblolly pine genome and provide the ability to identify genes that influence factors such as tree growth, wood quality, stress tolerance and resistance to disease. SIFG also conserved and supplied the plant tissue used in the genome sequencing project and provided quality control on the DNA samples that were sequenced.

###

Read more from the original source:
In the genome of loblolly pine lies hope for better resistance to a damaging disease

Summary: The collaboration, one of many IBM is planning to widen cognitive computing's footprint, will be the first Watson implementation for genomic research.

IBM's Watson business unit and the New York Genome Center will test a cognitive computing prototype aimed at allowing oncologists to better tailor cancer care.

IBM's Watson unit turnover: Worrisome or the norm?

IBM CEO Rometty: Watson, cognitive computing mainstreaming begins

IBM forms Watson Business Group: Will commercialization follow?

IBM Watson: How the Jeopardy-winning supercomputer was born, and what it wants to do next

The collaboration, one of many IBM is planning to widen cognitive computing's footprint, will be the first Watson implementation for genomic research.

Under the partnership:

Ultimately, IBM wants to use the Watson prototype for a clinical study by the New York Genome Center. The software and analytics tools have been under development for the past decade at IBM Research's Computational Biology Center.

The New York Genome Center specializes in experimental design, genome sequencing, bioinformatics and the computing and data storage infrastructure to crunch the data.

Go here to see the original:
IBM, New York Genome Center prep Watson prototype